Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis.
Abstract
Ticagrelor exerts anti-RCC effects via blockade of the EGFR/PI3K/AKT signaling axis, highlighting its translational potential and positioning this pathway as a therapeutic target and possible biomarker in RCC.
What are the key findings of this study?
Ticagrelor is a drug that can help fight a type of kidney cancer called renal cell carcinoma. It works by blocking certain signals (like EGFR, PI3K, and AKT) that cancer cells use to grow. This means it could be a new way to treat this cancer and help doctors find other patients who might benefit from it. 🩺
Key Points
Objective
The research aims to investigate the effects of ticagrelor on renal cell carcinoma growth through a specific signaling pathway.
Methods
- Experimental intervention with ticagrelor
- Analysis of RCC cell growth and signaling pathways
- Assessment of EGFR, PI3K, and AKT activation levels
Results
- Ticagrelor significantly reduces RCC cell growth
- Inhibition of the EGFR/PI3K/AKT signaling pathway observed
- Potential for ticagrelor as a therapeutic target and biomarker in RCC
What is the clinical evidence from this study?
Study Design
Other
Key Finding
Ticagrelor suppresses renal cell carcinoma growth by blocking the EGFR/PI3K/AKT signaling pathway, indicating its potential as a therapeutic agent.